Molecular testing is required to identify actionable mutations that are being identified in a growing proportion of NSCLC patients, with assessment of PD‐L1 expression levels guiding the use of immunotherapy agents in the remaining patient population.7, 24, 25. This evidence concerns the gene CD274 and non-small cell lung carcinoma.